Schizophrenia
Conditions
Keywords
adjunctive, atypical antipsychotics, add-on, Schizophrenia, psychosis
Brief summary
This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be randomized to receive either an FDA-approved drug or placebo in addition to the current treatment. Safety will be closely monitored through vital signs, various tests, and blood and urine samples.
Interventions
DRUGlamotrigine
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with schizophrenia. * Exhibits persistent positive symptoms that have persisted for a minimum of 3 months prior to screening. * Continuously taking 1-2 specific atypical antipsychotics for a minimum of 3 months and must be on a stable dose for at least 1 month prior to entering the study. * Participant or a legal guardian is able to understand and sign the consent form.
Exclusion criteria
* PANSS (Positive and Negative Syndrome Score) total score increases or decreases by more than 20% between the Screening and Baseline visits. * Predominant Axis I disorder other than schizophrenia within 6 months prior to screening. * History of clinically significant or unstable medical disorder or treatment that would interfere with the study. * History of autistic disorder or another pervasive developmental disorder, organic brain disease, dementia, stroke, epilepsy or a history of seizures requiring treatment (this does not include febrile seizures as a child), or those who have suffered a traumatic head injury. * Taking psychotropic or primarily centrally active medication at screening. * Use of antidepressant medications or mood stabilizers within 1 month of screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the total score of the Positive and Negative Symptom Scale (PANSS) at Week 12. | 12 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| - Efficacy - Change from baseline in PANSS positive symptoms at Week 12 - Change from baseline in the Scale for the Assessment of Negative Symptoms (SANS) at Week 12 - Change from baseline in PANSS general psychopathology symptoms at Week 12. | 12 Weeks |
Countries
Canada, United Kingdom, United States
Outcome results
None listed